Patents by Inventor Grégoire Vuagniaux

Grégoire Vuagniaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20240010731
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
    Type: Application
    Filed: June 2, 2023
    Publication date: January 11, 2024
    Applicants: Debiopharm International S.A., Merck Patent GmbH, Pfizer Inc.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
  • MEDICAMENT AND USE THEREOF FOR TREATING BACTERIAL INFECTIONS INVOLVING BIOFILM
    Publication number: 20230126947
    Abstract: The present invention relates to the use of Afabicin in a method of treating bacterial infections involving biofilm that contains Staphylococcus bacteria, wherein the method comprises administering Afabicin in combination with at least one further agent selected from lipopeptides, glycopeptides and lincosamides, such as Daptomycin and/or Vancomycin to the patient.
    Type: Application
    Filed: June 12, 2020
    Publication date: April 27, 2023
    Applicant: Debiopharm International S.A.
    Inventors: Justyna Nowakowska, Linda Kadi, Grégoire Vuagniaux
  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20220096436
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143, or another IAP antagonist, and a therapeutically effective amount of nivolumab, for the treatment of cancer, are provided.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 31, 2022
    Applicant: Debiopharm International S.A.
    Inventors: Sergio Adrian Szyldergemajn Altman, Grégoire Vuagniaux, Norbert Wiedemann, Daniela Purcea
  • COMBINATION TREATMENT OF HIV INFECTIONS
    Publication number: 20220016079
    Abstract: The present invention provides combination therapies for the treatment of HIV. The combination therapies of the present invention are aimed to reverse HIV latency and ultimately cure the disease. The combination therapies of the invention involve the use of an IAP inhibitor and the use of an immune checkpoint inhibitor.
    Type: Application
    Filed: November 26, 2019
    Publication date: January 20, 2022
    Applicant: Debiopharm International S.A.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann
  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20210198365
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
  • COMBINATION ANTI CANCER THERAPY WITH AN IAP ANTAGONIST AND AN ANTI PD-1 MOLECULE
    Publication number: 20210093645
    Abstract: Disclosed is the use of an IAP antagonist for pretreating a human subject diagnosed with a cancer to enhance the likelihood that a subsequent treatment with an anti-PD-1 molecule results in an anti-cancer response or to enhance the responsiveness of the subject's cancer to the subsequent treatment with the anti-PD-1 molecule. Also encompassed are methods of treatment of a subject's cancer, the methods comprising pretreatment of the subject with an IAP antagonist and subsequent treatment of the subject with an anti-PD-1 molecule.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 1, 2021
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Bruno Gavillet, Sergio Adrian Syldergemajn Altman
  • Medicament for treatment of diabetic foot infections
    Patent number: 10751351
    Abstract: The present invention provides means and methods for treating diabetic foot infections. In particular, drug compounds are provided that combine a high therapeutic activity against Staphylococcus Spp. bacteria with a high degree of bone penetration and vasodilatory effects. This unique combination of properties allows to accomplish high local concentrations of the drug at the site of infection even in diabetic foot patients typically having poor blood perfusion at the site of infection.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: August 25, 2020
    Assignee: Debiopharm International S.A.
    Inventors: Grégoire Vuagniaux, Linda Kadi, Frederick Wittke
  • MEDICAMENT FOR TREATMENT OF DIABETIC FOOT INFECTIONS
    Publication number: 20190054100
    Abstract: The present invention provides means and methods for treating diabetic foot infections. In particular, drug compounds are provided that combine a high therapeutic activity against Staphylococcus Spp. bacteria with a high degree of bone penetration and vasodilatory effects. This unique combination of properties allows to accomplish high local concentrations of the drug at the site of infection even in diabetic foot patients typically having poor blood perfusion at the site of infection.
    Type: Application
    Filed: February 27, 2017
    Publication date: February 21, 2019
    Inventors: Grégoire Vuagniaux, Linda Kadi, Frederick Wittke
  • Near full-genome assay of HCV drug resistance
    Patent number: 8911934
    Abstract: The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: December 16, 2014
    Assignees: Debiopharm SA, Katholieke Universiteit Leuven
    Inventors: Grégoire Vuagniaux, Jean-Maurice Dumont, Joke Snoeck, Sonia Van Dooren, Anne-Mieke Vandamme
  • Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events
    Patent number: 8889629
    Abstract: The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: November 18, 2014
    Assignee: Debiopharm International SA
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Grégoire Vuagniaux
  • NEAR FULL-GENOME ASSAY OF HCV DRUG RESISTANCE
    Publication number: 20140187765
    Abstract: Assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicants: Katholieke Universiteit Leuven, Debiopharm SA
    Inventors: Gregoire Vuagniaux, Jean-Maurice Dumont, Joke Snoeck, Sonia Van Dooren, Anne-Mieke Vandamme
  • Cycloundecadepsipeptide compounds and use of said compounds as a medicament
    Patent number: 8501683
    Abstract: At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis C infections or HCV induced disorders.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: August 6, 2013
    Assignee: Debio Recherche Pharmaceutique S.A.
    Inventors: Roland Wenger, Manfred Mutter, Patrick Garrouste, Robert Lysek, Olivier Turpin, Grégoire Vuagniaux, Valérie Nicolas, Laura Novaroli Zanolari, Rafael Crabbé
  • Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
    Patent number: 8450281
    Abstract: The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: May 28, 2013
    Assignee: Debiopharm S.A.
    Inventors: Paolo Bernardi, Gregoire Vuagniaux, Rafael Crabbe
  • CYCLOUNDECADEPSIPEPTIDE COMPOUNDS AND USE OF SAID COMPOUNDS AS A MEDICAMENT
    Publication number: 20110212057
    Abstract: At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis C infections or HCV induced disorders.
    Type: Application
    Filed: November 6, 2009
    Publication date: September 1, 2011
    Applicant: Debio Recherche Pharmaceutique S.A.
    Inventors: Roland Wenger, Manfred Mutter, Patrick Garrouste, Robert Lysex, Olivier Turpin, Grégoire Vuagniaux, Valérie Nicolas, Laura Novaroli Zanolari, Rafael Crabbé
  • NEAR FULL-GENOME ASSAY OF HCV DRUG RESISTANCE
    Publication number: 20100311038
    Abstract: The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.
    Type: Application
    Filed: October 31, 2008
    Publication date: December 9, 2010
    Applicants: DE-BIOPHARM SA, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Grégoire Vuagniaux, Jean-Maurice Dumont, Joke Snoeck, Sonia Van Dooren, Anne-Mieke Vandamme
  • Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin
    Patent number: 7772184
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: August 10, 2010
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay
  • NON-IMMUNOSUPPRESSIVE CYCLOSPORIN FOR TREATMENT OF ULLRICH CONGENITAL MUSCULAR DYSTROPHY
    Publication number: 20100041593
    Abstract: The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy.
    Type: Application
    Filed: January 3, 2008
    Publication date: February 18, 2010
    Inventors: Paolo Bernardi, Gregoire Vuagniaux, Rafael Crabbe
  • Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin
    Publication number: 20090081164
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Application
    Filed: August 26, 2008
    Publication date: March 26, 2009
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay
  • Use Of A Cyclic Undecapeptide For The Preparation Of A Medicament For Administration During Myocardial Ischaemic Events
    Publication number: 20090023640
    Abstract: The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.
    Type: Application
    Filed: January 10, 2006
    Publication date: January 22, 2009
    Applicant: DEBIOPHARM S.A.
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux
  • Use of selected cyclosporins for the treatment of hepatitis C infection
    Patent number: RE43371
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 8, 2012
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay